-
-
-
-
-
-
-
Intercept Pharmaceuticals (ICPT) Outlines It's NASH Plans at Analyst Day - Baird
-
-
-
-
-
-
-
Intercept Pharma (ICPT) Prices Offerings of Common Stock and Convertible Senior Notes due 2026
-
-
-
-
-
-
-
Intercept Pharmaceuticals (ICPT) PT Lowered to $253 at Baird on Ocaliva Label Uncertainty
-
-
-
-
-
-
-
Intercept (ICPT) NASH Trial Updates Offers 'Positives and Negatives' - Baird
-
-
-
-
-
-
-
Intercept (ICPT) Most Lucrative Opportunity Remains in NASH - Baird
-
-
-
-
-
-
-
Intercept's (ICPT) OCA Phase 2 in Japan Not 'Clear Miss'; Baird Maintains at 'Outperform'
-
-
-
-
-
-
-
Intercept Pharmaceuticals (ICPT) PT Raised at Baird on Increased Confidence in Accelerated Path to Approval
-
22,802 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All